XML 36 R23.htm IDEA: XBRL DOCUMENT v3.22.2.2
Summary of Significant Accounting Policies (Tables)
6 Months Ended 10 Months Ended 12 Months Ended
Jun. 30, 2022
Dec. 31, 2021
Dec. 31, 2021
Schedule of calculation of basic and diluted net income (loss) per ordinary share The following table sets forth the calculation of basic and diluted earnings per share for the periods indicated based on the weighted average number of common shares outstanding:
 
    
Three Months Ended June 30,
    
Six Months Ended June 30,
 
    
2022
    
2021
    
2022
    
2021
 
Numerator
           
Net loss available to Class A Unit holders
   $ (22,131    $ (12,725    $ (89,617    $ (24,334
Denominator
           
Weighted average Class A Units outstanding, basic and diluted
     186,500,000        140,109,890        186,500,000        131,160,221  
Net loss per Class A Unit
           
Net loss per Class A Unit, basic and diluted
     (0.12      (0.09      (0.48      (0.19
Antidilutive securities
           
Class B Units
     27,100,937        7,767,122        27,100,937        7,767,122  
  The following table sets forth the calculation of basic and diluted earnings per share for the periods indicated based on the weighted average number of common shares outstanding:
 
    
Years Ended December 31,
 
    
2021
    
2020
 
Numerator
                 
Net loss available to Class A Unit holders
   $ (55,146    $ (26,749
Denominator
                 
Weighted average Class A Units outstanding, basic and diluted
     150,706,849        104,986,301  
Net loss per Class A Unit
                 
Net loss per Class A Unit, basic and diluted
   $ (0.37    $ (0.25
Schedule of accrued expenses Accrued expenses as presented in the Condensed Consolidated Balance Sheets as of June 30, 2022 and December 31, 2021 consisted of the following (in thousands):
 
    
June 30,

2022
    
December 31,

2021
 
Compensation
   $ 1,545      $ 1,832  
Clinical study related costs
     222        2,031  
Accrued legal costs
     3,193        964  
Manufacturing improvement costs
     652        4,164  
Other accrued expenses
     572        222  
  
 
 
    
 
 
 
Total accrued expenses and other
   $ 6,184      $ 9,213  
  
 
 
    
 
 
 
 
Accrued expenses which have been presented on the consolidated balance sheets as of December 31, 2021 and 2020 consisted of the following (in thousands):
 
    
December 31,
2021
    
December 31,
2020
 
Compensation
   $ 1,832      $ 1,085  
Clinical study related costs
     2,031        1,154  
Facility expansion costs
     19        1,709  
Accrued legal
     964        —    
Manufacturing improvement costs
     4,164        —    
Other accrued expenses
     203        548  
    
 
 
    
 
 
 
Total accrued expenses and other
   $ 9,213      $ 4,496  
    
 
 
    
 
 
 
Schedule of estimated useful lives The estimated useful lives are as follows:
 
Computer equipment and software   
3-5
years
Furniture and equipment   
5-7
years
Leasehold improvements
   remainder of lease term
  The estimated useful lives are as follows:
 
Computer equipment and software
  
3-
5
years
Furniture and equipment
  
5-
7
years
Leasehold improvements
   remainder of lease term
Schedule of fixed assets
Fixed assets consisted of the following (in thousands):
 
    
June 30,

2022
    
December 31,

2021
 
Furniture and equipment
   $ 2,367      $ 2,180  
Computer equipment and software
     719        569  
Leasehold improvements
     10,538        10,517  
Construction in progress
     694        351  
Less: accumulated depreciation
     (3,461      (2,259
  
 
 
    
 
 
 
Total fixed assets, net
   $ 10,857      $ 11,358  
  
 
 
    
 
 
 
 
Fixed assets consisted of the following (in thousands):
 
    
December 31,
2021
    
December 31,
2020
 
Furniture and equipment
   $ 2,180      $ 2,011  
Computer equipment and software
     569        130  
Leasehold improvements
     10,517        76  
Construction in progress
     351        7,854  
Less: accumulated depreciation
     (2,259      (1,157
    
 
 
    
 
 
 
Total fixed assets, net
   $ 11,358      $ 8,914  
    
 
 
    
 
 
 
Schedule of intangible asset The following table summarizes information related to the Company’s assembled workforce intangible asset (in thousands):
 
    
June 30,

2022
    
December 31,

2021
 
Gross carrying amount
   $ 1,073      $ 1,073  
Accumulated amortization
     753        645  
  
 
 
    
 
 
 
Net carrying amount
   $ 320      $ 428  
  
 
 
    
 
 
 
  The following table summarizes information related to the Company’s assembled workforce intangible asset (in thousands):
 
    
December 31,
2021
    
December 31,
2020
 
Gross carrying amount
   $ 1,073      $ 1,073  
Accumulated amortization
     645        431  
    
 
 
    
 
 
 
Net carrying amount
   $ 428      $ 642  
    
 
 
    
 
 
 
Social Capital Suvretta Holdings Corp. III [Member]      
Schedule of calculation of basic and diluted net income (loss) per ordinary share
At June 30, 2022 and December 31, 2021, the Class A ordinary shares subject to possible redemption reflected in the condensed consolidated balance sheets are reconciled in the following
table:
 
Gross proceeds
   $ 250,000,000  
Less:
        
Class A ordinary shares issuance costs
     (12,479,666
Plus:
        
Accretion of carrying value to redemption value
     12,487,990  
Class A ordinary shares subject to possible redemption, December 31,
2021
  
 
250,008,324
 
Less: Remeasurement of carrying value to redemption value
    
(8,324
)
 
    
 
 
 
Class A ordinary shares subject to possible redemption, March 31, 2022
  
 
250,000,000
 
Add: Remeasurement of carrying value to redemption value
     371,095  
    
 
 
 
Class A ordinary shares subject to possible redemption, June 30, 2022
  
$
250,371,095
 
    
 
 
 
At December 31, 2021, the Class A ordinary shares subject to possible redemption reflected in the balance sheet are reconciled in the following table:
 
Gross proceeds
   $ 250,000,000  
Less:
        
Class A ordinary shares issuance costs
     (12,479,666
Plus:
        
Increase of carrying value to redemption value
     12,487,990  
    
 
 
 
Class A ordinary shares subject to possible redemption
  
$
250,008,324
 
    
 
 
 
 
Schedule of Class A Ordinary shares reflected in the Balance Sheets
 
The following table reflects the calculation of basic and diluted net loss per ordinary share (in dollars, except per share
amounts):
 
 
 
Three Months Ended June 30,
 
 
Six Months Ended
June 30,
 
 
For the Period from
January 20,
2021 (inception)
through
June 30,
 
 
 
2022
 
 
2021
 
 
2022
 
 
2021
 
 
 
Class A
 
 
Class B
 
 
Class A
 
 
Class B
 
 
Class A
 
 
Class B
 
 
Class A
 
 
Class B
 
Basic and diluted net loss per ordinary share
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Numerator:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Allocation of net loss, as adjusted
 
$
(1,825,123
 
$
(444,891
 
$
  
 
 
$
(143
 
$
(5,025,922
 
$
(1,225,117
 
$
  
 
 
$
(5,325
Denominator:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Basic and diluted weighted average shares outstanding
 
 
25,640,000
 
 
 
6,250,000
 
 
 
  
 
 
 
5,500,000
 
 
 
25,640,000
 
 
 
6,250,000
 
 
 
  
 
 
 
5,500,000
 
Basic and diluted net loss per ordinary share
 
$
(0.07
 
$
(0.07
 
$
  
 
 
$
(0.00
 
$
(0.20
 
$
(0.20
 
$
  
 
 
$
(0.00
The following table reflects the calculation of basic and diluted net loss per ordinary share (in dollars, except per share amounts):
 
 
  
For the Period from

February 25, 2021 (Inception)
Through December 31, 2021
 
 
  
Class A
 
  
Class B
 
Basic and diluted net loss per ordinary share
  
     
  
     
Numerator:
  
     
  
     
Allocation of net loss
 
$
(1,675,346
)

 
$

(649,283
)

Denominator:
 
    
 
  
 
 
 
Basic and diluted weighted average shares outstanding
 
   15,101,877
 
  
 
5,852,751
 
 
 
  
 
 
  
 
 
 
Basic and diluted net loss per ordinary share
 
$

(0.11
)

  
$

(0.11
)